Nicole Johnson-Barnes, CFA
Senior Research Analyst, Global Equities
As the market and world-at-large were elated by Pfizer’s announcement of positive trial results for its COVID-19 vaccine this week, we all brace for a winter run of global lockdowns and extensive virus spread mitigation measures. In the last three weeks, a number of European countries have reimposed nationwide limitations. Notably, starting October 30th, France reinstituted its spring lockdown rules which restrict residents to their homes except for trips to buy essential goods, medical appointments, and one hour of physical activity. Germany’s “lockdown light” began on November 2nd, closing all bars, restaurants, and theaters and limiting access to retail shops, though schools remain open. And within the U.S., we have seen several states roll out pandemic constraints as well, including Illinois, Maryland, and Washington.
This chart provides a quick snapshot of COVID-19 case tallies as of November 12th. Soberingly, these figures are rising at a pace much faster than the initial wave. We have seen how the spring cases and restrictions hampered productivity and brought a few nations into recessionary territory. In October, the IMF released revised global GDP growth estimates that were mildly positive, reducing the estimate from -4.9% to -4.4% on the back of eased summer restrictions and an influx of fiscal stimulus. While it is expected that fiscal stimulus measures will continue and could dampen the economic blow, global growth will remain depressed for 2020 and into 2021 as we work through this second wave.
On Saturday, November 7th, Joe Biden was declared the winner of the presidential election and will become the 46th president…
In this week’s chart of the week, we look at the estimated growth of Gross Domestic Product (GDP) — the…
The third quarter of 2020 featured a major rebound in economic data amid an intense battle for the presidency and…
Research alerts keep you updated on our latest research publications. Simply enter your contact information, choose the research alerts you would like to receive and click Subscribe. Alerts will be sent as research is published.
We respect your privacy. We will never share or sell your information.
If you have questions or need further information, please contact us directly and we will respond to your inquiry within 24 hours.Contact Us >